Andrew Gengos

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Bothell, WA
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Michael D. Bookman, Attorney-in-Fact for Andrew Gengos
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Andrew Gengos

Form 4 holding CFO and Chief Business Officer

Athira Pharma, Inc.

Security class
Common Stock
Shares / value
97,532
Estimated value
$55,203
Report date
05 Sep 2024
Price
$0.5660
Ownership
Direct
Form 4 holding CFO and Chief Business Officer

Athira Pharma, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
280,000
Estimated value
Report date
14 Feb 2024
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Chief Business Officer

Cyteir Therapeutics, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
35,000
Estimated value
Report date
22 Feb 2022
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Andrew Gengos

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .